Literature DB >> 29579604

All roads lead to IL-6: A central hub of cardiometabolic signaling.

Peter Libby1, Viviane Zorzanelli Rocha2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29579604     DOI： 10.1016/j.ijcard.2018.02.062

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  15 in total

1.  Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease.

Authors:  Luca Liberale; Fabrizio Montecucco; Jean-Claude Tardif; Peter Libby; Giovanni G Camici
Journal:  Eur Heart J       Date:  2020-08-14       Impact factor: 29.983

2.  A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD.

Authors:  Kristen L Nowak; Rahul Kakkar; Matt Devalaraja; Larry Lo; Wansu Park; Joga Gobburu; Douglas Kling; Michael Davidson; Michel Chonchol
Journal:  Kidney360       Date:  2020-12-04

3.  Sleep exerts lasting effects on hematopoietic stem cell function and diversity.

Authors:  Cameron S McAlpine; Máté G Kiss; Faris M Zuraikat; David Cheek; Giulia Schiroli; Hajera Amatullah; Pacific Huynh; Mehreen Z Bhatti; Lai-Ping Wong; Abi G Yates; Wolfram C Poller; John E Mindur; Christopher T Chan; Henrike Janssen; Jeffrey Downey; Sumnima Singh; Ruslan I Sadreyev; Matthias Nahrendorf; Kate L Jeffrey; David T Scadden; Kamila Naxerova; Marie-Pierre St-Onge; Filip K Swirski
Journal:  J Exp Med       Date:  2022-09-21       Impact factor: 17.579

4.  Interleukin-6 Predicts Carotid Plaque Severity, Vulnerability, and Progression.

Authors:  Joseph Kamtchum-Tatuene; Luca Saba; Mirjam R Heldner; Michiel H F Poorthuis; Gert J de Borst; Tatjana Rundek; Stavros K Kakkos; Seemant Chaturvedi; Raffi Topakian; Joseph F Polak; Glen C Jickling
Journal:  Circ Res       Date:  2022-06-17       Impact factor: 23.213

5.  Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.

Authors:  Paul M Ridker; Jean G MacFadyen; Robert J Glynn; Gary Bradwin; Ahmed A Hasan; Nader Rifai
Journal:  Eur Heart J       Date:  2020-08-14       Impact factor: 29.983

6.  Laquinimod Protects Against TNF-α-Induced Attachment of Monocytes to Human Aortic Endothelial Cells (HAECs) by Increasing the Expression of KLF2.

Authors:  Tiechao Jiang; Wenhao Zhang; Zhongyu Wang
Journal:  Drug Des Devel Ther       Date:  2020-04-30       Impact factor: 4.162

Review 7.  Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.

Authors:  Eunhye Ji; Sahmin Lee
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

8.  Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.

Authors:  Debmalya Barh; Alaa A Aljabali; Murtaza M Tambuwala; Sandeep Tiwari; Ángel Serrano-Aroca; Khalid J Alzahrani; Bruno Silva Andrade; Vasco Azevedo; Nirmal Kumar Ganguly; Kenneth Lundstrom
Journal:  Biomedicines       Date:  2021-05-17

9.  The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.

Authors:  Chiara Baldini; Francesca Romana Moriconi; Sara Galimberti; Peter Libby; Raffaele De Caterina
Journal:  Eur Heart J       Date:  2021-11-07       Impact factor: 35.855

10.  Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction.

Authors:  Hilde E Groot; Lawien Al Ali; Iwan C C van der Horst; Remco A J Schurer; Hindrik W van der Werf; Erik Lipsic; Dirk J van Veldhuisen; Jacco C Karper; Pim van der Harst
Journal:  Clin Res Cardiol       Date:  2018-10-26       Impact factor: 5.460
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.